{"id":1015478,"date":"2026-10-29T19:35:00","date_gmt":"2026-10-29T23:35:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/"},"modified":"2026-10-29T19:35:00","modified_gmt":"2026-10-29T23:35:00","slug":"trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/","title":{"rendered":"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum<\/b><\/p>\n<p>WESTMINSTER, Colo.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nTriSalus Life Sciences\u00ae Inc. (Nasdaq: TLSI) (\u201cTriSalus\u201d or the \u201cCompany\u201d), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum. Management will participate in one-on-one meetings and present a corporate overview on Wednesday, November 11, at 11:30 a.m. ET. Click <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FDTQRjGm3o3uirpQXXoaaDj%2Fguest_book%3Fsession_id%3DHvKzBTes6rCpRC892QyHcN&amp;esheet=54631603&amp;newsitemid=20261029675511&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=727cc41577e1df250dfeedaac47dac96\">here<\/a> for a link to the live webcast.<\/p>\n<p>\nA webcast replay of the corporate overview will be available for 90 days following the presentation in the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.trisaluslifesci.com%2Fnews-events%2Fevents-presentations&amp;esheet=54631603&amp;newsitemid=20261029675511&amp;lan=en-US&amp;anchor=Events&amp;index=2&amp;md5=f31f610ab252151b6770fa265c6d77f2\">Events<\/a> section of the TriSalus Investor website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.trisaluslifesci.com%2F&amp;esheet=54631603&amp;newsitemid=20261029675511&amp;lan=en-US&amp;anchor=www.investors.trisaluslifesci.com.&amp;index=3&amp;md5=164042ccdc953f3476f4b7e20cdc7418\">www.investors.trisaluslifesci.com.<\/a><\/p>\n<p><b>About TriSalus Life Sciences<\/b><\/p>\n<p>\nTriSalus Life Sciences\u00ae is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies. The Company\u2019s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company\u2019s four FDA-cleared devices and two devices commercialized under Letters to File use its proprietary Pressure-Enabled Drug Delivery\u2122 (PEDD) approach to deliver a range of therapeutics: the five TriNav\u00ae Infusion Systems and the Pancreatic Retrograde Venous Infusion System. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company\u2019s investigational immunotherapeutic candidate, is designed to treat the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development. In partnership with leading cancer centers across the country \u2013 and by leveraging deep immuno-oncology expertise and inventive technology development \u2013 TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftrisaluslifesci.com%2F&amp;esheet=54631603&amp;newsitemid=20261029675511&amp;lan=en-US&amp;anchor=trisaluslifesci.com&amp;index=4&amp;md5=a107da51e557e1d65c6e88c4d47d4bb3\">trisaluslifesci.com<\/a> and follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Ftrisaluslifesci&amp;esheet=54631603&amp;newsitemid=20261029675511&amp;lan=en-US&amp;anchor=X+%28formerly+Twitter%29&amp;index=5&amp;md5=d2e64402950a58d0c77b1da25bacee24\">X (formerly Twitter)<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ftrisaluslifesciences&amp;esheet=54631603&amp;newsitemid=20261029675511&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=8b86e4b5b25a04cb5f7b2f8850e8e56b\">LinkedIn<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261029675511r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261029675511\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261029675511\/en\/<\/a><\/span><\/p>\n<p><b>For Investor and Media Inquiries:<br \/>\n<\/b><br \/>David Patience<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investor.relations@trisaluslifesci.com\">investor.relations@trisaluslifesci.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Colorado United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Medical Devices Clinical Trials Health Technology Biotechnology General Health Pharmaceutical Health Science Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261029675511\/en\/2854086\/3\/TriSalus_Life_Sciences.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum WESTMINSTER, Colo.&#8211;(BUSINESS WIRE)&#8211; TriSalus Life Sciences\u00ae Inc. (Nasdaq: TLSI) (\u201cTriSalus\u201d or the \u201cCompany\u201d), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum. Management will participate in one-on-one meetings and present a corporate overview on Wednesday, November 11, at 11:30 a.m. ET. Click here for a link to the live webcast. A webcast replay of the corporate overview will be available for 90 days &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1015478","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum WESTMINSTER, Colo.&#8211;(BUSINESS WIRE)&#8211; TriSalus Life Sciences\u00ae Inc. (Nasdaq: TLSI) (\u201cTriSalus\u201d or the \u201cCompany\u201d), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum. Management will participate in one-on-one meetings and present a corporate overview on Wednesday, November 11, at 11:30 a.m. ET. Click here for a link to the live webcast. A webcast replay of the corporate overview will be available for 90 days &hellip; Continue reading &quot;TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-29T23:35:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261029675511r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum\",\"datePublished\":\"2026-10-29T23:35:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/\"},\"wordCount\":466,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261029675511r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/\",\"name\":\"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261029675511r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-10-29T23:35:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261029675511r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261029675511r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/","og_locale":"en_US","og_type":"article","og_title":"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum - Market Newsdesk","og_description":"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum WESTMINSTER, Colo.&#8211;(BUSINESS WIRE)&#8211; TriSalus Life Sciences\u00ae Inc. (Nasdaq: TLSI) (\u201cTriSalus\u201d or the \u201cCompany\u201d), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum. Management will participate in one-on-one meetings and present a corporate overview on Wednesday, November 11, at 11:30 a.m. ET. Click here for a link to the live webcast. A webcast replay of the corporate overview will be available for 90 days &hellip; Continue reading \"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-29T23:35:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261029675511r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum","datePublished":"2026-10-29T23:35:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/"},"wordCount":466,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261029675511r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/","name":"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261029675511r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-10-29T23:35:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261029675511r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261029675511r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trisalus-life-sciences-to-participate-in-the-canaccord-genuity-medtech-diagnostics-and-digital-health-and-services-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1015478"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1015478\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1015478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1015478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1015478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}